PEDEvidence
Semaglutide research
Human

What did semaglutide achieve in the direct comparison?

13.7% weight reduction

72 weeks; maximum tolerated semaglutide 1.7/2.4 mg versus tirzepatide 10/15 mg; adults without diabetes.

Demonstrated findings

Participants assigned semaglutide lost an average of 13.7% of body weight at 72 weeks, versus 20.2% with tirzepatide.

What might this mean? ยท interpretation

Semaglutide produced substantial weight reduction in this trial, with a smaller average reduction than the comparator.

What might this mean, and what would change the interpretation?

This result applies to the studied regimens and population. Weight change does not establish preservation of muscle or long-term cardiovascular benefit.

What would clarify this: Endpoint-specific comparisons using matched populations and durations.

Download evidence card

An editorial reading note with a primary-source link. Interpretation is identified separately from observed results.